Skip to main content

Table 1 Study Exclusion Criteria

From: Effects of inhaled nitric oxide on hemostasis in healthy adults treated with heparin: a randomized, controlled, blinded crossover study

Exclusion Criteria

Administration of any investigational drug in the period 0 to 3 months before entry to the study (0 to 4 months if the previous investigational drug was a new chemical entity)

A need for any medication (including OTC drugs, e.g., aspirin) during the period 0 to 7 days before entry to the study

Existence of any surgical or medical condition which, in the judgment of the clinical investigator, might interfere with the absorption, distribution, metabolism or excretion of the drug

Presence or history of allergy requiring treatment

Donation or loss of greater than 400 ml of blood in the period 0 to 12 weeks before entry to the study

Serious adverse reaction or hypersensitivity to any drug, especially heparin

History of easy bruising

Personal or family history or coagulation or bleeding disorders, cerebral hemorrhage, or reasonable suspicion or vascular malformations, including aneurysms

History of important bleeding, e.g., hematemesis or melena, severe or recurrent epistaxis or hemoptysis

Known heparin resistance

Consumption of aspirin in any form, or of other non-steroidal anti-inflammatory drugs within the 3 weeks prior to the final eligibility check

Rectal bleeding, including that presumed from hemorrhoids within 3 months prior to screening

Surgery or significant trauma within the 3 months prior to screening

Significant epigastric pain or indigestion either chronically or within 4 weeks prior to screening

Platelet aggregation response of 40% to 10 μmol/L ADP and 2 μg/mL collagen

Abnormal platelet aggregation response to arachidonic acid

Inability to communicate or co-operate with the investigator because of a language problem, poor mental development or impaired cerebral function

Smokers

Objection by the subject's general practitioner to his/her patient's participation in the study